NETHERLANDS - Gilde Healthcare supports EUR 16.6m Agendia funding

The round was subscribed by an international syndicate of both new and existing investors and is the largest private placement in the Benelux healthcare technology sector this year.

Based in Amsterdam, Agendia develops and commercialises cancer diagnostic tests. The company commercialises MammaPrint, a prognostic test that predicts the risk of breast cancer recurrence.

The new funding will be used to accelerate the commercialisation of MammaPrint® in the US market.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• Benelux